Navigation Links
ViroPharma to Present at Three November Healthcare Conferences
Date:11/6/2008

EXTON, Pa., Nov. 6 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Vincent Milano, president and chief executive officer of ViroPharma, will present at the Rodman & Renshaw Annual Global Investment Conference at 12:25 P.M. ET on Wednesday, November 12, 2008. The conference is being held at the New York Palace Hotel.

ViroPharma also announced that Colin Broom, vice president, chief scientific officer of ViroPharma will present at the Lazard Capital Markets 5th Annual Healthcare Conference at 9:30 A.M. ET on Wednesday, November 19, 2008. The conference is being held at the St. Regis Hotel in New York.

William Roberts, vice president, corporate communications of ViroPharma will present at the Needham & Company Focus on Infectious Disease Conference at 9:30 A.M. ET on Thursday, November 20, 2008. The conference is being held at Needham & Company's corporate headquarters in New York.

ViroPharma's presentations will be webcast live for investors through http://www.viropharma.com and available for a period of 14 days following the conferences.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R) (vancomycin hydrochloride capsules, USP), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains, and Cinryze(TM) (C1 inhibitor (human)) for routine
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
2. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
3. ViroPharma to Present at Three October Healthcare Conferences
4. ViroPharma to Present at Three September Healthcare Conferences
5. ViroPharma To Acquire Lev Pharmaceuticals
6. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
7. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
8. ViroPharma to Present at Two Upcoming Healthcare Conferences
9. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
10. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
11. ViroPharma to Present at the Susquehanna Financial Group Second Annual Significant Options in Healthcare Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)..., ST.LOUIS,Nov.24/PRNewswire-FirstCall/--Sigma-Ald...eNASDAQOMXconferenceonTuesday,December1stat1:45PMG...vialiveaudiobroadcastovertheInternetavailableat h...rscanclickthe"Webcast"icontoaccessthisfile. ,, ...ScienceandHighTechnologycompany.Itschemicalandbioc...
(Date:11/24/2009)..., SANMATEO,Calif.,Nov.24/PRNewswire-FirstCall/--Ne...anyfocusedondevelopingandcommercializingnovelpainm...o,PresidentandChiefExecutiveOfficer,isscheduledtop...nce,tobeheldDecember1-2,2009atTheNewYorkPalaceHote...lieri,ChiefFinancialOfficer,willbeavailabletorespo...
(Date:11/24/2009)... ,Primaryefficacyendpointhasbeenmetforpatientswith..., QUEBECCITY,Nov.24/PRNewswire-FirstCall/-AEternaZ...globalbiopharmaceuticalcompanyfocusedonendocrineth...afromaPhase2studywithitstargetedcytotoxicpeptideco...ancedorrecurrentendometrialcancer.Inapersonalizedh...
(Date:11/24/2009)..., REDWOODCITY,Calif.,Nov.24/PRNewswire-FirstCall/-...atRandyScott,GenomicHealth,sExecutiveChairman,will...enceinNewYorkCityonTuesday,December1,2009at10:00a....webcastofthepresentation,visittheInvestorRelations...genomichealth.com .Pleaseconnecttothewebsiteatleas...
Breaking Biology Technology:NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Genomic Health to Present at Piper Jaffray Health Care Conference 2
...apeutics,Inc. (MTI), a company that discovers and ...gs, announces that it has retained Marquant Partne...se on its strategic and partnering,opportunities, ...lders., This appointment follows a significant am...financial and pharmaceutical companies after its,a...
...a-,Aldrich Corporation announced today that it wil...dnesday, March 19, 2008 at its Life Science & High...uis, Mo. 63103, The event will begin at 8:30 a.m....be webcast over the Sigma-Aldrich website at, http...Sigma-Aldrich is a leading Life Science and High,T...
...Deliver Electronic X-ray-Based, Therapy Directly ...tings, SUNNYVALE, Calif., March 17 Xoft, Inc., t...ance from the U.S. Food & Drug,Administration (FDA...m, a,proprietary technology platform designed to d...iation treatment in minimally-shielded,clinical se...
Other Biology Technology:Mercury Therapeutics, Inc: Marquant Appointed to Advise on Strategic and Partnering Opportunities 2Mercury Therapeutics, Inc: Marquant Appointed to Advise on Strategic and Partnering Opportunities 3FDA Clears Expanded Use of Xoft's Axxent(R) Electronic Brachytherapy System for all Radiation Therapy Indications 2
(Date:11/23/2009)...alifornia biomedical engineer and cardiologist Tzu...p clinicians distinguish cardiac emergencies requi...eable with drugs and lifestyle change. , Angiogr...teries feeding the heart, offer an inside view of ...els, often revealing deposits of a dangerous fatty...
(Date:11/23/2009)...General Medical Sciences (NIGMS), part of the Nati...3 million for grants in scientific areas it identi...the GO grant program to stimulate biomedical resea...erican Recovery and Reinvestment Act (Recovery Act...o have a significant impact on a field of biomedic...
(Date:11/23/2009)... is Director of the Interuniversity Professorship ...and the University of the Basque Country. The Prof...as other experts such as researchers in the fields...ts in ethics. , The Interuniversity Professorshi... of Deusto and the Basque Country was created in 1...
Breaking Biology News(10 mins):Stable plaque or heart attack plaque? USC researcher builds new sensor to tell which is which 2NIGMS invests in scientific Grand Opportunities with Recovery Act funds 2NIGMS invests in scientific Grand Opportunities with Recovery Act funds 3Research and legislation should go hand in hand, as much as possible 2A tiny frozen microbe may hold clues to extraterrestrial life 8822 1A tiny frozen microbe may hold clues to extraterrestrial life 8822 2Advance in understanding cellulose synthesis 8820 1Advance in understanding cellulose synthesis 8820 2Advance in understanding cellulose synthesis 8820 3Keep Safety in Mind While Cooling Off in the Water 48824 1Keep Safety in Mind While Cooling Off in the Water 48824 2
... Four hundred researchers tapping the massive flow...30 to share their recent developments at the 2nd A...tute (DOE JGI) User Meeting. DOE JGI is the world,...ughput DNA sequencing available to a diverse resea...erwise would not have access to such a resource to...
... A team of Canadian researchers, lead by Dr. Susan...iction and Mental health (CAMH), discovered a dist...mposed of two different types of dopamine receptor...n understanding and treating schizophrenia. , Publ...f Sciences USA (Rashid et al., 2007), this importa...
... Some day, heart attack survivors might have a pat...t, to replace areas that died during their attack....et new ones that can grow in place, rather than be...ged or weak blood vessels might get a new “natural...se possibilities are all within reach, and could t...
Other Biology News:New dopamine brain target discovered 2Engineering the heart piece by piece 2Engineering the heart piece by piece 3Engineering the heart piece by piece 4
Mouse Anti-DNA-PKcs, phospho (Thr2609) Monoclonal Antibody, Unconjugated, Clone 10B1 from BioLegend
Rabbit Anti-Histamine H2 Receptor Polyclonal Antibody, Unconjugated from IMGENEX
NF kappa B Related Sampler Kit from BD Biosciences Pharmingen
Glycogen Coprecipitant from Bioline
Biology Products: